
Opinion|Videos|July 9, 2024
Interchangeability Impacting Biosimilar Uptake
The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Has interchangeability impacted biosimilar adoption? If not, why?
- What value do switching studies bring to interchangeable biosimilars?
- Does this data matter more than the designation?
- Do pharmacies and providers value interchangeability?
- Have pharmacies begun acting upon interchangeability with automatic substitutions?
- What value do switching studies bring to interchangeable biosimilars?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement

